Pooja Devi, MD
Pathology and Laboratory Medicine
Headshot of Pooja Devi, MD

Pooja Devi, MD

Pathology and Laboratory Medicine
Accepting new patients
Sees patients age 18 and up
Penn Pathology and Laboratory Medicine HUP
Headshot of Pooja Devi, MD
Penn Medicine Provider

About me

  • Assistant Professor of Clinical Pathology and Laboratory Medicine

My education and training

  • Ghulam Muhammad Mahar Medical CollegeMedical School
  • Aga Khan UniversityResidency
  • Saint Barnabas Medical CenterResidency
  • Hospital of the University of PennsylvaniaFellowship

Spoken languages

English
English

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
Dr. Devi is a Penn Medicine physician.

Qualifications and experience

Treatments and conditions

Research

Publications

Olivia J Leung, Esther Baranov, Isairis Peralta Valerio, Robin Collingwood, Natalie Respond, Don Siegel, Pooja Devi, Kristen M. Stashek Comparison of intestinal histopathological changes following teclistamab, BCMA-directed CAR T, CD19-directed CAR T and rituximab therapies , Histopathology: 2026


Ruella M, Paruzzo L, Chong ER, Chong EA, Landsburg DJ, Nasta SD, Devi P, Michener P, Stella F, Carturan A, Napier EB, Van Deerlin VM, Porazzi P, Levine BL, Frey N, Porter DL, Fraietta JA, Svoboda J, June CH, Schuster SJ Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas , New England Journal of Medicine, 394(24): 2026


Carturan A, Angelos MG, Guruprasad P, Patel RP, Pajarillo R, Lee A, Espie D, Zhang Y, Chiang YH, Xie W, Rodriguez JL, Harris J, Devi P, Afolayan-Oloye OI, Xu J, Sussman JH, Elghawy O, Yang A, Barsouk A, Cho JH, Shaw CE, Singh E, Ugwuanyi O, Paruzzo L, Stella F, Liu S, Nason S, Imparato A, Rotolo A, Lemoine J, Barrett DM, Posey A, Rook AH, Pillai V, Bagg A, Pileri SA, Liu D, Tan K, Schuster SJ, Teachey DT, Porazzi P, Ruella M Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies , Blood, 147(16): 2026


Ho M, Paruzzo L, Noll JH, Stella F, Devi P, Ndeupen S, Day YA, Chen GM, Cohen IJ, Ramirez-Fernandez A, Waxman A, Kapur S, Chen F, Xu R, Huff A, Jarocha D, Patel V, Bochi-Layec AC, Ramasubramanian R, Liu S, Bouvier R, de Souza VB, Patel H, Li Z, Carturan A, Michener P, Hopkins CR, Koucky O, Minehart J, Dimitri A, Nabar NR, Hasanali ZS, Ciccarelli BT, Hung P, Williams E, Bartoszek R, Lavorando M, Mohan S, Gonzalez VE, Porazzi P, Bhoj VG, Apostolidis SA, Vogl D, Porter DL, Scholler J, Diorio C, Roche AM, Everett JK, Bushman FD, Nathanson KL, Stadtmauer EA, Susanibar-Adaniya SP, Garfall AL, Ruella M, Cohen AD, Fraietta JA CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy , Nature Medicine, 32(2): 2026,702-716


Federico Stella, Michael Schneider, Luca Paruzzo, Julia Han Noll, Pooja Devi, Victor Babatunde, Elise Chong, Matthew Ho, Colin Thomas, Michael Cook, Nasheed Hossain, Jordan Carter, Ziyu Li, Melody Tan, Peter Michener, Puneeth Guruprasad, Vrutti Patel, Antonio Imparato, Alberto Carturan, Jean Lemoine, Vitor Souza, Patrizia Porazzi, Joseph Fraietta, Stefan Barta, Sunita Dwivedy Nasta, Jakub Svoboda, Stephen J. Schuster, Ivan Maillard, Daniel Landsburg, Marco Ruella Naive CD4+ at apheresis and disease control at infusion are associated with improved efficacy in second-line CAR T-cells , Blood: 2025


Alice Wang, Luca Paruzzo, Martina Bonomi, Chia-Hui Chen, Ivan Cohen, John DiMaio, Kyung Jin Ahn, Peter Michener, Jaryse Harris, Arati Inamdar, Pooja Devi, Emeline Chong, Siddharth Bhattacharyya, Vrutti Patel, Patrizia Porazzi, Joseph Fraietta, Stephen Schuster, Fabio Luciani, Marco Ruella, Kai Tan Type II interferon-driven crosstalk between effector memory CART and myeloid cells is associated with CART19 resistance in relapsed refractory large B-cell lymphomas , Blood: 2025


Luca Paruzzo, Amelia Mantione, Elise Chong, Sunita Dwivedy Nasta, Daniel Landsburg, Jordan Carter, Michael Cook, Eugenio Fardella, Ashkan Bigdeli, Vrutti Patel, Antonio Imparato, Colin Thomas, Vitor Souza, Alberto Carturan, Federico Stella, Martina Pucillo, Pooja Devi, Emily Tomasulo, Stefan Barta, Stephen Schuster, Eitan Halper-Stromberg, Marco Ruella, Jakub Svoboda Large B-cell lymphoma following CD19-directed CART-cell therapy failure: Impact of CAR construct on disease features and outcomes of subsequent therapies , Blood: 2025


Pai E, Matsumoto Y, Nelluri S, Dou D, Devi P, Priori S, Amankulor N, Alonso-Basanta M, Singh O, Abdullaev Z, Aldape K, Desai A, Mohan S, P. Nasrallah M. Molecularly Defined Oligodendroglioma Evolving to Osseous Metastases , Journal of Neuropathology & Experimental Neurology, 84(10): 2025,954–959


Ho M, Paruzzo L, Minehart J, Voruganti T, Devi P, Vogl D, Cohen A, Garfall A, Waxman A, Kapur S, Stadtmauer E, Adaniya S, Longworth S. Haematologica. 2025 Feb 6. doi: 10.3324/haematol.2024.286675 Nontuberculous mycobacterial infections following teclistamab in multiple myeloma , Haematologica. 2025 Feb 6: 2025


Li Xingchen, Devi P, Saksena A A Rare Case of Diffuse Large B Cell Lymphoma Co-occurring with Small Lymphocytic Leukemia: De Novo Process or Richter's Syndrome , American Journal of Clinical Pathology, 162: 2024,S77–S78